Data is at the heart of applicable genomics. As the volume and depth of genomic data grows, bioinformaticians are translating the data into interpretable patterns leading to new biological insight.
As part of the Next Generation Children project at Addenbrooke’s Hospital and Cambridge University, all seriously ill children in England with unexplained disorders will be able to have their genomes analysed from 2020. The project should mean quicker diagnoses for families in the future.
The FDA has cleared the most expensive drug yet, Novartis’ gene therapy drug Zolgensma, for introduction to the market. Zolgensma, created to combat spinal muscular atrophy, has been priced at $2.125 million, or $425,000 annually over five years.
It has now been 16 years since the Human Genome Project sequenced the first ever human genome: in that time, as has been mentioned in previous editions of this report, more than 500,000 genomes have been sequenced, generating enough data to drastically raise computational resource usage and create a need for rapid innovation to offset […]
GEDMatch, the DNA database which made news recently for its instrumental role in solving cold criminal cases in the US, has blocked law enforcement from accessing information for the millions of people on its system.
UK Biobank has released a vast tranche of genetic data to health researchers around the world, offering an unprecedented resource to enhance understanding of human biology and aid in therapeutic discovery. This follows a brief exclusive research period for Regeneron and GSK. Additional tranches of data will be released over the next two years.
Two molecules which switch off CRISPR could be used to make gene editing therapies safer in the future. Harvard University’s Amit Choudhary and his colleagues said the molecules could stop CRISPR making unintended changes to DNA, potentially harming the individual.
Genetic research is a big data problem without researchers generally having access to this “big” genomic and medical data. Not only has it been nearly impossible to access enough relevant data to support research, but analysing the data has been slow and challenging due to its sheer volume. To counter this, in recent years a number of pharmaceutical companies have announced large-scale collaborations around genomic data to uncover novel drug targets, validate existing drug pipelines, predict response, and expand therapeutics use. We discuss some of the biggest and most recent.
Front Line Genomics’ “Biodata Analysis and Management – Genome Analytics, Interoperability, and Data Life Cycle” report isn’t just an update of our old Genomic Data 101 guides: packed with new information on AI and machine learning,. data discoverability and data interoperability, it is much much more.
Genomic compression expert PetaGene has become a NetApp Alliance Partner, the company announced recently, a move set to improve performance and reduce costs for researchers using large datasets within the genomics field.
Cambridge and London researchers have created a database of DNA mutation “fingerprints” which can be used to determine the environmental factors contributing to a patient’s tumour. The study, published in Cell journal, can determine 41 different environmental agents linked to cancer, including the traces left in lung tumours by chemicals linked particularly to tobacco smoke.
Compression software company Petagene has announced the addition of “Petagene Protect” to its suite of genomic data projects, giving users the ability to encrypt and manage access to genomic data, as well as ensuring compliance with all relevant regulations.
Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
D4: Pharma is a highly-select gathering of 80-100 very senior and experienced pharma professionals responsible for making important decisions, as well as turning innovation and new ideas into measurable progress.
With so many talks and panels occurring across our four stages and Live Lounge, we understand that it can be pretty hard to pick out the most unmissable discussions at the festival this year. Given the conundrum, we thought we’d help out! We’ve selected a couple of talks and panels occurring across the two days which we think will be incredibly interesting and enormously informative for a whole range of people.
With both our own festival and the wider life sciences sector moving rapidly towards a more integrative and holistic treatment of different -omics in research and drug development, we thought we’d get Dr. Dennis Wang, Lecturer in Bioinformatics and Genomics Medicine at the NIHR Sheffield Biomedical Research Centre, to talk us through the shift towards multi-omics.
